|
1) |
Lee LN, Stock RG, Stone NN. Role of hormonal therapy in the management of intermediate to high risk prostate cancer treated with permanent radioactive seed implantation. Int J Radiat Oncol Biol Phys. 2002;52:444-52. |
2) |
Merrick GS, Butler WM, Galbreath RW, et al. Five-year biochemical outcome following permanent interstitial brachytherapy for clinical T1-T3 prostate cancer. Int J Radiat Oncol Biol Phys. 2001;51(1):41-8. |
3) |
Potters L, Torre T, Ashley R, et al. Examining the role of neoadjuvant androgen deprivation in patient undergoing prostate brachytherapy. J Clin Oncol. 2000;18:1187-92 |
4) |
Joseph J, Al-Qausieh B, Ash D, et al. Prostate-specific antigen relapse-free survival in patients with localized prostate cancer treated by brachytherapy. BJU Int. 2004;94:1235-8. |
5) |
Kucway R, Vicini F, Huang R, et al. Prostate volume reduction with androgen deprivation therapy before interstitial brachytherapy. J Urol. 2002;167:2443-7. |